A5021095019- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Occupational and environmental lung diseases
- Prostate Cancer Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Prostate Cancer Treatment and Research
- Pancreatic and Hepatic Oncology Research
- Platelet Disorders and Treatments
- Global Cancer Incidence and Screening
- Lymphoma Diagnosis and Treatment
- Genomics and Rare Diseases
- Intraperitoneal and Appendiceal Malignancies
- Multiple Myeloma Research and Treatments
- Epigenetics and DNA Methylation
- Pleural and Pulmonary Diseases
- Neutropenia and Cancer Infections
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging and Pathology Studies
- Childhood Cancer Survivors' Quality of Life
- Hemoglobinopathies and Related Disorders
- Testicular diseases and treatments
University of Chicago
2015-2025
University of Chicago Medical Center
2011-2024
Susan Thompson Buffett Foundation
2024
University of Chicago Medicine Comprehensive Cancer Center
2024
Cancer Genetics (United States)
2014-2023
Northwestern Medicine
2014
Dana-Farber Cancer Institute
2012
Beth Israel Deaconess Medical Center
2011
Harvard University
2011
Indiana University Bloomington
2007
In 2012, the US Preventive Services Task Force (USPSTF) discouraged prostate-specific antigen (PSA) -based prostate cancer screening. Previous USPSTF recommendations did not appreciably alter Therefore, we designed a trend analysis to determine population-based impact of 2012 recommendation.The nationally representative National Health Interview Survey was used estimate proportion men age 40 years and older who saw physician were screened for in 2013. An externally validated 9-year mortality...
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, blast phase) usually diagnosed chronic phase developed countries. Tyrosine kinase inhibitor (TKI) therapy highly effective treatment option for patients with phase–CML. The primary goal TKI phase–CML prevent disease progression...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following guideline development process as outlined in Methodology Manual . follow Conflict Interest Policy Clinical Practice other guidance (“Guidance”) provided by is not a or definitive guide to treatment options. It intended voluntary use clinicians should be used conjunction independent professional judgment. Guidance may applicable all patients,...
Purpose For patients who elect to have prostate cancer screening, the optimal time discontinue screening is unknown. Our objective was describe rates and predictors of prostate-specific antigen (PSA) among older men in United States. Methods Data were extracted from population-based 2000 2005 National Health Interview Survey (NHIS). PSA defined as a test part routine exam within past year. Demographic, socioeconomic, functional characteristics collected, validated 5-year estimated life...
BACKGROUND Prostate‐specific antigen (PSA) screening for prostate cancer remains controversial. Most groups recommend informed decision making men with 10 years of remaining life expectancy. The primary objective this observational cohort study was to investigate the association between predicted 9‐year mortality and among American aged ≥65 in 2005 2010. second analyze proportions who discussed their physicians. METHODS Data were extracted from 2010 National Health Interview Surveys. Men...
Individuals with germ line variants associated hereditary hematopoietic malignancies (HHMs) have a highly variable risk for leukemogenesis. Gaps in our understanding of premalignant states HHMs hampered efforts to design effective clinical surveillance programs, provide personalized preemptive treatments, and inform appropriate counseling patients. We used the largest known comparative international cohort germline RUNX1, GATA2, or DDX41 variant carriers without (HMs) identify patterns...
In its landmark paper about Standards and Guidelines for the Interpretation of Sequence Variants, American College Medical Genetics Genomics (ACMG), Association Molecular Pathology (AMP) did not address how to use tumor data when assessing pathogenicity germline variants. The Clinical Genome Resource (ClinGen) established a multidisciplinary working group, Germline/Somatic Variant Subcommittee (GSVS) with this focus. GSVS implemented survey determine current practices integrating somatic...
Not available.
Abstract Background Multiple myeloma (MM) is characterized by abnormal plasma cell proliferation in the bone marrow, leading to symptoms like osteolytic lesions, anemia, hypercalcemia, and elevated serum creatinine. RNA-sequencing-based prognostic indicators for MM have shown promise stratifying risk assessing first-line treatment options. This study uses machine learning techniques leverages RNA-sequencing, clinical, biochemical data from Myeloma Research Foundation (MMRF) CoMMpass cohort...
The use of biopsy-derived pharmacodynamic biomarkers is increasing in early-phase clinical trials. It remains unknown whether drug development accelerated or enhanced by their use. We examined the impact on subsequent through a comprehensive analysis phase I oncology studies from 2003 to 2010 and publications citing original trials.We conducted search identify examine including between 2010. Characteristics those were extracted analyzed, along with outcomes biomarker data. then compiled...
Once thought to be exceedingly rare, the advent of next-generation sequencing has revealed a plethora germline predisposition disorders that confer risk for hematopoietic malignancies (HMs). These syndromes are now recognized much more common than previously thought. The recognition susceptibility allele in an individual impacts clinical management and health surveillance strategies index patient relatives who share causative DNA variant. Challenges accurate testing include lack familiarity...
Abstract Current therapies for high-grade TP53 -mutated myeloid neoplasms (≥10% blasts) do not offer a meaningful survival benefit except allogeneic stem cell transplantation in the minority who achieve complete response to first line therapy (CR1). To identify reliable pre-therapy predictors of first-line (CR1) and outcomes, we assembled cohort 242 individuals with ≥10% blasts well-annotated clinical, molecular pathology data. Key outcomes examined were CR1 & 24-month (OS24). In this...
Abstract The genomics era has facilitated the discovery of new genes that predispose individuals to bone marrow failure (BMF) and hematological malignancy (HM). We report ETS-related gene (ERG), a novel, autosomal dominant BMF/HM predisposition gene. ERG is highly constrained transcription factor critical for definitive hematopoiesis, stem cell function, platelet maintenance. colocalizes with other factors, including RUNX family 1 (RUNX1) GATA binding protein 2 (GATA2), on promoters or...
Importance Patients with mesothelioma often have next-generation sequencing (NGS) of their tumor performed; tumor-only NGS may incidentally identify germline pathogenic or likely (P/LP) variants despite not being designed for this purpose. It is unknown how frequently patients P/LP detected via NGS. Objective To determine the prevalence incidental mesothelioma. Design, Setting, and Participants A series 161 unrelated from a high-volume program had performed during April 2016 to October 2021....